ArticleJournal of translational medicine2026
Helicobacter pylori promotes hepatocarcinogenesis by abrogating the protective effect of intestinal Bacteroides acidifaciens in females.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) exhibits sexual dimorphism, with a lower incidence observed in females. However, the mechanisms underlying the disruption of this protective effect remain inadequately understood. Helicobacter pylori (Hp) is associated with HCC and can cause gut microbiota imbalances that promote HCC progression. This study explored how Hp might influence female susceptibility to HCC via the gut-liver axis, focusing on gut bacteria and their metabolites.
methodsA Hp-infected DEN + CCl₄-induced HCC mouse model was established, and a cohort of 186 HCC patients was analyzed. Fecal metagenomics and serum metabolomics were employed to identify Hp-responsive gut microbes and metabolites. The therapeutic potential of Bacteroides acidifaciens (Ba) and its metabolite 4‑hydroxybenzyl alcohol (4‑HBA), alone or combined with Hp eradication, was evaluated in mouse models and in mechanistic cell-based assays.
resultsHp increased tumor burden and fibrosis especially in female mice. Hp-positive female patients exhibited larger tumors, more advanced disease stages, higher cirrhosis incidence, and poorer overall survival compared to Hp-negative females. Hp also reduced gut microbiota diversity and decreased female-enriched Ba. The Ba-specific metabolite 4-HBA, which is higher in females and reduced by Hp, suppressed TGF‑β/SMAD signaling by binding to TGFBR2, thereby inhibiting hepatic stellate cell activation and HCC cell proliferation. Ba/4-HBA alleviated Hp-induced liver pathology in both sexes, with the combination of Hp eradication and Ba/4-HBA treatment proving more effective than eradication alone in females.
conclusionsHp exacerbates hepatic fibrogenesis and HCC in females by depleting Ba and its metabolite 4-HBA, which inhibits TGF-β/SMAD signaling through binding to TGFBR2. Supplementation with Ba/4-HBA, particularly when combined with Hp eradication, tend to be a promising microbiota-metabolite-targeted strategy for attenuating female HCC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.